Abstract
Infection with a high-risk type of the human papillomavirus (HPV) is a major contributing factor in the vast majority of cervical cancers. Dissemination of the HPV vaccine is critical in reducing the risk of the disease. This descriptive review of HPV vaccine uptake in papers published between 2006 and 2011 focuses on studies conducted in girls and young women. In the United States, rates of immunization as per the protocol for teens (age 13–17 years) range from 6% to 75% and those for young women (age 18–26 years) range from 4% to 79%, although the samples and data collection methods vary. The epidemiology of HPV, the mechanisms of action, protocols for vaccine immunization, rates of uptake, and barriers to vaccination at the policy, provider, and patient levels are reviewed. Various intervention techniques are described, and policy-level programs, such as legislation supporting mandates, subsidized public education, and cost-reduction initiatives, are also explored. Increased distribution of the HPV vaccine in school-based clinics, evidencebased scripts for provider counseling of young patients and their parents, concurrent immunizations to adolescents, prevention visits, greater patient education and outreach, and the dissemination of academic detailing can help to boost vaccine uptake, particularly in underresourced communities. Population-based surveillance is necessary for robust estimates of uptake over time. Additional research is needed to comprehensively examine socio-demographic, psychosocial, and sociocultural factors that predict vaccine uptake according to the protocol. Increased study of the vaccine’s long-term effectiveness, in both males and females and among extended age groups, is warranted.
Similar content being viewed by others
References
Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus in young women. N Engl J Med. 2006;354;2645–2654.
Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis. 2006;194:1044–1057.
Giuliano AR. Human papillomavirus vaccination in males. Gynecol Oncol. 2007;107(suppl. 1):S24–S26.
Reiter PL, Brewer NT, McRee AL, Gilbert P, Smith JS. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis. 2010;37:197–203.
Zimet G, Rosenthal SL. HPV vaccine for males: issues and challenges. Gynecol Oncol. 2010;117(suppl.):S26–S31.
Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(suppl.): 3036–3046.
Michels KB, zur Hausen H. HPV vaccine for all. Lancet. 2009;374:268–270.
Reiter PL, McRee AL, Kadis JA, Brewer NT. HPV vaccine and adolescent males. Vaccine 2011 [epub ahead of print].
Liddon N, Hood J, Wynn BA, Markowitz LE. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health. 2010;46:113–123.
Vaccarella S, Franceschi S, Clifford GM, et al. Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomark Prev. 2010;19:2379–2388.
Centers for Disease Control and Prevention. Human Papillomavirus: HPV Information for Clinicians. Atlanta, GA: Centers for Disease Control and Prevention; 2007. Available at: www.cdc.gov/std/hpv/common-clinicians/ClinicianBrofp.pdf. Accessed June 15, 2011.
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–2150.
Scarinci IC, Garcia FAR, Kobetz E, et al. Cervical cancer prevention: new tools and old barriers. Cancer. 2010;116:2531–2542.
Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78–93.
Cui Y, Baldwin SB, Wiley DJ, Fielding JE. Human papillomavirus vaccine among adult women: disparities in awareness and acceptance. Am J Prev Med. 2010;39:559–563.
Millen JC, Ginde AA, Anderson AT, Fang P, Camargo CA Jr. Multicenter study of knowledge about human papilloma virus and attitudes among emergency department patients. J Pediatric Adolesc Gynecol. 2009;22:356–359.
Hughes J, Cates JR, Liddon N, Smith JS, Gottlieb SL, Brewer NT. Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiol Biomarkers Prevention. 2009;18:363–372.
Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199:926–35.
Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–314.
Markowitz LE. Update and new vaccine recommendations: human papillomavirus vaccines. Centers for Disease Control and Prevention Web site. Available at: www.cdc.gov/vaccines/ed/ciinc/downloads/Nov_09/NICRDnetconf2009final.ppt. Accessed June 15, 2011.
Muñoz N, Manalastas R Jr., Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373:1949–1957.
Dunne EF, Datta SD, Markowitz LE. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Cancer. 2008;113(suppl.): 2995–3003.
Monk BJ, Herzog TJ. The new era of cervical cancer prevention: HPV vaccination. Gynecol Oncol. 2008;109(suppl. 1):S1–S3.
Downs LS Jr., Scarinci I, Einstein MH, Collins Y, Flowers L. Overcoming the barriers to HPV vaccination in high-risk populations in the US. Gynecol Oncol. 2010;117:486–490.
Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med. 2000;124:672–681.
de Rijke JM, van der Putten HWHM, Lutgens LCHW, et al. Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of the Netherlands, 1986–1996. Eur J Cancer. 2002;38:2041–2047.
Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–615.
Hildesheim A, Hadjimichael O, Schwartz PE, et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol. 1999;180:571–577.
Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health. 1995;85:791–794.
Wright TC Jr., Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304–309.
The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383–1392.
Wiley DA, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv. 2006;61(suppl. 1):S3–S14.
Lacey CJN, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPVrelated conditions: HPV-6/11 disease. Vaccine. 2006;24(suppl. 3):S35–S41.
Vaccarella S, Francheschi S, Herrero R, et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev. 2006;15:326–333.
Rosenfeld WD, Rose E, Vermund SH. Schreiber K, Burk RD. Follow-up evaluation of cervicovaginal human papillomavirus infection in adolescents. J Pediatr. 1992;121:301–311.
Widdice LE, Breland DJ, Jonte J, et al. Human papillomavirus concordance in heterosexual couples. J Adolesc Health. 2010;47:151–159.
Burchell AN, Richardson H, Mahmud SM, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol. 2006;163:534–543.
Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813–819.
Muñoz N, Bosch FX, de Sanjosé S, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527
Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in highgrade cervical lesions and cervical cancer: a metaanalysis. Br J Cancer. 2003;89:101–105.
Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1157–1164.
Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467–475.
FDA approves new vaccine for prevention of cervical cancer [press release]. Bethesda, MD: Food and Drug Administration; October 16, 2009.
Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med. 2010;10:7–17.
Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009;8:1663–1679.
United States Department of Health and Human Services. Vaccines excipient and media summary, part 2. Excipients included in the U.S. Vaccines, by vaccine. In: Atkinson W, Wolfe S, Hamborsky J, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th edition. Washington, DC: Public Health Foundation; 2011.
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943.
The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927.
The FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.
Harper DM, Franco EL, Wheeler CM, et al. HPV Vaccine Study Group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–1255.
Stanley M. Prophylactic human papillomavirus vaccines: will they do their job? J Intern Med. 2010;267:251–259.
Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine. 2009;27(suppl. 1):A46–A53.
Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol. 2010;118(suppl. 1):S12–S17.
Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J. 2010;29:95–101.
Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5:332–340.
Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750–757.
Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol. 2009;114:1170–1178.
Wise LD, Wolf JJ, Kaplanski CV, Pauley CJ, Ledwith BJ. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. Birth Defects Res B Dev Reprod Toxicol. 2008;83:561–572.
Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009;114:1179–1188.
Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ. 2010;340:c712.
Advisory Committee on Immunization Practices. Vaccines for Children Program. Vaccines to prevent human papillomavirus Resolution No.010/09-1. Centers for Disease Control and Prevention Web site. Available at: www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/1009hpv-508.pdf. Accessed June 15, 2011.
Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915–1923.
Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E. Age-based programs for vaccination against HPV. Value Health. 2007;12:697–707.
Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769.
Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J. Cost-utility analysis of vaccination against HPV in Israel. Vaccine. 2007;25:6677–6691.
Coupé VMH, Berkhof J, Bulkmans NWJ, Snijders PJF, Meijer CJLM. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer. 2008;98:646–651.
Jain N, Stokley S, Yankey D. Vaccination coverage among adolescents aged 13–17 years — United States, 2007. MMWR. 2008;57:1100–1103.
Stokley S, Dorell C, Yankey D. National, state, and local area vaccination coverage among adolescents aged 13–17 years — United States, 2008. MMWR. 2009;58:997–1001.
Dorell C, Stokley S, Yankey D, Cohn A. National, state, and local area vaccination coverage among adolescents aged 13–17 years — United States, 2009. MMWR. 2010;59:1018–1023.
Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey — Adult 2007. Prev Med. 2009;48:426–431.
Schiller JS, Euler GL. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. Centers for Disease Control and Prevention Web site. Available at: www.cdc.gov/nchs/data/hestat/vaccine_coverage/vaccine_coverage.pdf. Accessed June 15, 2011.
2009 Adult Vaccination Coverage, NHIS. The National Health Interview Survey (NHIS). Centers for Disease Control and Prevention Web site. Available at: www.cdc.gov/vaccines/stats-surv/nhis/2009-nhis.htm. Accessed June 15, 2011.
Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health. 2009;45:453–462.
Allen JD, Othus MKD, Shelton RC, et al. Parental decision making about the HPV vaccine. Cancer Epidemiol Biomarkers Prev. 2010;19:2187–2198.
Grant D, Kravitz-Wirtz N, Breen N, Tiro JA, Tsui J. One in four California adolescent girls have had human papillomavirus vaccination. Policy Brief UCLA Cent Health Policy Res. 2009 Feb;(PB2009-3):1–6.
Gottlieb SL, Brewer NT, Sternberg MR, et al. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J Adolesc Health. 2009;45:430–437.
Reiter PL, Cates JR, McRee A-L, et al. Statewide HPV vaccine initiation among adolescent females in North Carolina. Sex Transm Dis. 2010;37:549–556.
Tan W, Viera AJ, Rowe-West B, Grimshaw A, Quinn B, Walter EB. The HPV vaccine: are dosing recommendations being followed? Vaccine. 2011;29:2548–2554.
Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc. 2010;84:864–870.
Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol. 2008;111:1103–1110.
Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol. 2010;171:357–367.
Dempsey A, Cohn L, Dalton V, Ruffin M. Worsening disparities in HPV vaccine utilization among 19–26 year old women. Vaccine. 2011;29:528–534.
Rosenthal SL, Rupp R, Zimet GD, et al. Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes. J Adolesc Health. 2008;43:239–245.
Cook RL, Zhang J, Mullins J, et al. Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health. 2010;47:596–599.
Yeganeh N, Curtis D, Kuo A. Factors influencing HPV vaccination status in a Latino population; and parental attitudes towards vaccine mandates. Vaccine. 2010;28:4186–4191.
Gerend MA, Weibley E, Bland H. Parental response to human papillomavirus vaccine availability: uptake and intentions. J Adolesc Health. 2009;45:528–531.
Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a universitybased health system. Vaccine. 2010;28:989–995.
Schluterman NH, Terplan M, Lydecker AD, Tracy JK. Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine. 2011;29:3767–3772.
Allen JD, Mohllajee AP, Shelton RC, Othus MKD, Fontenot HB, Hanna R. Stage of adoption of the human papillomavirus vaccine among college women. Prev Med. 2010;48:420–425.
Roberts ME, Gerrard M, Reimer R, Gibbons FX. Mother-daughter communication and human papillomavirus vaccine uptake by college students. Pediatrics. 2010;125:982–989.
Bednarczyk RA, Birkhead GS, Morse DL, Doleyres H, McNutt L-A. Human papillomavirus vaccine uptake and barriers: association with perceived risk, actual risk and race/ethnicity among female students at a New York State university, 2010. Vaccine. 2011;29:3138–3143.
Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health. 2009;33:365–370.
Ogilvie G, Anderson M, Marra F, et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med. 2010;7:e1000270.
Brabin L, Roberts SA, Stretch R, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ. 2008;336:1056–1058.
Rondy M, van Lier A, van de Kassteele J, Rust L, de Melker H. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine. 2010;28:2070–2075.
Fagot J-P, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine. 2011;29:3610–3616.
Pruitt SL, Schootman M. Geographic disparity, area poverty, and human papillomavirus vaccination. Am J Prev Med. 2010;38:525–533.
Brewer NT, Gottlieb SL, Reiter PL, et al. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a highrisk geographic area. Sex Transm Dis. 2011;38:197–204.
Daley MF, Crane LA, Markowitz LE, et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics. 2010;126:425–433.
McCave EL. Influential factors in HPV vaccination uptake among providers in four states. J Community Health. 2010;35:645–652.
Lee GM, Santoli JM, Hannan C, et al. Gaps in vaccine financing for underinsured children in the United States. JAMA. 2007;298:638–643.
Freed GL, Cowan AE, Gregory S. Clark SJ. Variation in provider vaccine purchase prices and payer reimbursement. Pediatrics. 2008;122:1325–1331.
Keating KM, Brewer NT, Gottlieb SL, Liddon N, Ludema C, Smith JS. Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health. 2008;43(suppl.):S61–S67.
Gottlieb SL, Brewer NT, Smith JS, Keating KM, Markowitz LE. Availability of human papillomavirus vaccine at medical practices in an area with elevated rates of cervical cancer. J Adolesc Health. 2009;45:438–444.
Rand CR, Szilagyi PG, Albertin C, Auinger P. Additional health care visits needed among adolescents for human papillomavirus vaccine delivery within medical homes: a national study. Pediatrics. 2007;120:461–466.
Szilagyi PG, Bordley C, Vann JC, et al. Effect of patient reminder/recall interventions on immunization rates: a review. JAMA. 2000;284:1820–1827.
Herzog TJ, Huh WK, Downs LS, Smith JS, Monk BJ. Initial lessons learned in HPV vaccination. Gynecol Oncol 2008;109(suppl.):S4–S11.
Goldstein MG, Whitlock EP, DePue J. Planning Committee of the Addressing Multiple Behavioral Risk Factors in Primary Care Project. Multiple behavioral risk factor interventions in primary care. Summary of research evidence. Am J Prev Med. 2004;27:61–79.
Whitlock EP, Orleans CT, Pender N, Allan J. Evaluating primary care behavioral counseling interventions: an evidence-based approach. Am J Prev Med. 2010;22:267–284.
Kahn JA, Cooper HP, Vadaparampil ST, et al. Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-yearold girls: a statewide survey of Texas physicians. Cancer Epidemiol Biomarkers Prev. 2009;18:2325–2332.
Brawley OW, Berger MZ. Cancer and disparities in health: perspectives on health statistics and research questions. Cancer. 2008;113:1744–1754.
Goel MS, Wee CC, McCarthy EP, Davis RB, Ngo-Metzger Q, Phillips RS. Racial and ethnic disparities in cancer screening: the importance of foreign birth as a barrier to care. J Gen Intern Med. 2003;18:1028–1035.
Coughlin SS, Thompson TD, Hall HI, Logan P, Uhler RJ. Breast and cervical carcinoma screening practices among women in rural and nonrural areas of the United States, 1998–1999. Cancer. 2002;94:2801–2812.
Ogedegbe G, Cassells AN, Robinson CM, et al. Perceptions of barriers and facilitators of cancer early detection among low-income minority women in community health centers. J Natl Med Assoc. 2005;97:162–170.
Boyer LE, Williams M, Callister LC, Marshall ES. Hispanic women’s perceptions regarding cervical cancer screening. J Obstet Gynecol Neonatal Nurs. 2001;30:240–245.
HPV vaccine: updated May 2011. National Conference of State Legislatures Web site. Available at: www.ncsl.org/default.aspx?tabid=14381#2009. Accessed June 15, 2011.
Dempsey AF, Mendez D. Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate. J Adolesc Health. 2010;47:242–248, 248.e1–248.e6.
Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med. 2006;355:2389–2391.
Gostin LO, DeAngelis CD. Mandatory HPV vaccination: public health vs. private wealth. JAMA. 2007;297:1921–1923.
Haber G, Malow RM, Zimet GD. The HPV vaccine mandate controversy. J Pediatr Adolesc Gynecol. 2007;20:325–331.
Vaccination requirements for IV applicants. U.S. Department of State Web site. Available at: travel.state.gov/visa/immigrants/info/info_1331.html. Accessed June 15, 2011.
Wright TC, Van Damme P, Schmitt H-J, Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine. 2006;24(suppl. 3):S3/122–S3/131.
Sheinfeld Gorin S, Gauthier J, Hay J, Miles A, Wardle J. Cancer screening and aging: research barriers and opportunities. Cancer. 2008;113(suppl.): 3493–3504.
Briss PA, Rodewald LE, Hinman AR, et al. The Task Force on Community Preventive Services. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. Am J Prev Med. 2000;18(suppl.): 97–140.
Rothman SM, Rothman DJ. Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA. 2009;302:781–786.
Hulscher MEJL, Wensing M, van der Weijden T, Grol R. Interventions to implement prevention in primary care. Cochrane Database Syst Rev. 2001:CD000362.
Sheinfeld Gorin S, Gemson D, Ashford A, et al. Cancer education among primary care physicians in an underserved community. Am J Prev Med. 2000;19:53–58.
Gorin SS, Wang C, Raich P, Bowen DJ, Hay J. Decision making in cancer primary prevention and chemoprevention. Ann Behav Med. 2006;32:179–187.
Ashford A, Gemson D, Sheinfeld Gorin SN, et al. Cancer screening and prevention practices of innercity physicians. Am J Prev Med. 2000;19:59–62.
Dietrich AJ, Sox CH, Tosteson TD, Woodruff CB. Durability of improved physician early detection of cancer after conclusion of intervention support. Cancer Epidemiol Biomarkers Prev. 1994;3:335–340.
Chan SSC, Cheung TH, Lo WK, Chung TK. Women’s attitudes on human papillomavirus vaccination to their daughters. J Adolesc Health. 2007;41:204–207.
Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8:188–194.
Dempsey AF, Zimet GD, Davis RL, Koutsky, L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486–1493.
Gerend MA, Shepherd JE. Using message framing to promote acceptance of the human papillomavirus vaccine. Health Psychol. 2007;26:745–752.
Cox DS, Cox AD, Sturm L, Zimet G. Behavioral interventions to increase HPV vaccination acceptability among mothers of young girls. Health Psychol. 2010;29:29–39.
Leader AE, Weiner JL, Kelly BJ, Hornik RC, Cappella JN. Effects of information framing on human papillomavirus vaccination. J Womens Health (Larchmt). 2009;18:225–233.
Juraskova I, Bari RA, O’Brien MT, McCaffery KJ. HPV vaccine promotion: does referring to both cervical cancer and genital warts affect intended and actual vaccination behavior? Womens Health Issues. 2011;21:71–79.
Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11:39–44.
Koutsky LA, Ault KA, Wheeler CM, et al. Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645–1651.
Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102:325–339.
Perkins RB. Efficacy data and HPV vaccination studies. JAMA. 2009;302:2659.
Chesson H. The cost-effectiveness of HPV vaccination in the United States. Department of Health Web site. Available at: www.advisorybodies.doh.gov.uk/jcvi/foi-HPVsubgrouppapers0707-ACIPcosteffectiveness.pdf. Accessed June 15, 2011.
Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig D. Early effect of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377:2085–2092.
Link MW, Ahluwalia IB, Euler GL, Bridges CB, Chu SY, Wortley PM. Racial and ethnic disparities in influenza vaccination coverage among adults during the 2004–2005 season. Am J Epidemiol. 2006;163:571–578.
Stein CR, Wortley PM, Singleton JA. Racial/ethnic disparities in influenza and pneumococcal vaccination levels among persons aged ≥65 years — United States, 1989–2001. MMWR. 2003;52:958–962.
Singleton JA, Greby SM, Wooten KG, Walker FJ, Strikas R. Influenza, pneumococcal, and tetanus toxoid vaccination of adults — United States, 1993–1997. MMWR. 2000;49:39–62.
Stanley M. Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis. 2010;23:70–75.
Fiebig D, Haas M, Johar M, Viney R. Evaluating changes in women’s attitudes towards cervical screening following a screening promotion campaign and a free vaccination program. Paper presented at: 7th World Congress on Health Economics; July 12–15, 2009: Beijing, China.
Lazcano-Ponce E, Herrero R, Muñoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer. 2001;91:412–420.
McCauley MM, Stokley S, Stevenson J, Fishbein DB. Adolescent vaccination: coverage achieved by ages 13–]15 years, and vaccinations received as recommended during ages 11–12 years, National Health Interview Survey 1997–2003. J Adolesc Health. 2008;43:540–547.
Christian WJ, Christian A, Hopenhayn C. Acceptance of the HPV vaccine for adolescent girls: analysis of state-added questions from the BRFSS. J Adolesc Health. 2009;44:437–445.
Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003–2004. J Infect Dis. 2009;200:1059–1067.
Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med. 2007;45:107–114.
Lazcano-Ponce E, Rivera L, Arillo-Santillán E, Salmerón J, Hernández-Avila M, Muñoz N. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res. 2001;32:243–252
Marlow LAV, Wardle J, Forster AS, Waller J. Ethnic differences in human papillomavirus awareness and vaccine acceptability. J Epidemiol Comm Health. 2009;63:1010–1015.
Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007;40:108–115.
Tissot AM, Zimet GD, Rosenthal SL, Bernstein DI, Wetzel C, Kahn JA. Effective strategies for HPV vaccine delivery: the views of pediatricians. J Adolesc Health. 2007;41:119–125.
Freed G, Clark SJ, Hibbs BF, Santoli JM. Parental vaccine safety concerns: the experiences of pediatricians and family physicians. Am J Prev Med. 2004;26:11–14.
Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians’ intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005;37:502–510.
Daley MF, Liddon N, Crane LA, et al. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics. 2006;118:2280–2289.
Abma JC, Martinez GM, Mosher WD, Dawson BS. Teenagers in the United States: sexual activity, contraceptive use, and childbearing 2002. Vital Health Stat. 2004;23:1–48.
Zimet G. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health. 2005;37(suppl.):S17–S23.
Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis. 2000;27:49–52.
Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine. 2006;24:3087–3094.
Gorin SS. HPV knowledge among physicians and their low-income patients: survey findings and approaches for change. Program/Proceedings of the Eurogen Conference 2006, G423CO165:57–62.
Montaño DE, Kasprzyk D, Carlin L, et al. STDprevention counseling practices and human papillomavirus opinions among clinicians with adolescent patients — United States, 2004. MMWR. 2006;55:1117–1120.
Allen JD, Coronado GD, Williams RS, et al. A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability. Vaccine. 2010;28:4027–4037.
Rosenthal SL, Weiss TW, Zimet GD, Ma L, Good MB, Vichnin MD. Predictors of HPV vaccine uptake among women aged 19–26: importance of a physician’s recommendation. Vaccine. 2011;29:890–895.
Zimet GD, Stupiansky NW, Weiss TW, Rosenthal SL, Good MB, Vichnin MD. Influence of patient’s relationship status and HPV history on physicians’ decisions to recommend HPV vaccination. Vaccine. 2011;29:378–381
Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol. 2007;110:87–95.
Freed GL, Clark SJ, Cowan AE, Coleman MS. Primary care physician perspectives on providing adult vaccines. Vaccine. 2011;29:1850–1854.
Kharbanda EO, Stockwell MS, Fox HW, Andres R, Lara M, Rickert VI. Text message reminders to promote human papillomavirus vaccination. Vaccine. 2011;29:2537–2541.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sheinfeld Gorin, S.N., Glenn, B.A. & Perkins, R.B. The human papillomavirus (HPV) vaccine and cervical cancer: Uptake and next steps. Adv Therapy 28, 615–639 (2011). https://doi.org/10.1007/s12325-011-0045-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0045-x